We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Premier Biomedical Inc (PK) | USOTC:BIEI | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0001 | -6.25% | 0.0015 | 0.0014 | 0.0016 | 0.0016 | 0.0014 | 0.0014 | 2,719,333 | 18:08:24 |
July 21, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, DC 20549
|
Re: |
Premier Biomedical, Inc. |
|
Request for Withdrawal of Registration Statement on Form S-1 |
|
|
File No. 333-218250 |
Ladies and Gentlemen:
Pursuant to Rule 477 of the Securities Act of 1933, as amended (the “ Securities Act ”), Premier Biomedical, Inc. (the “ Company ”) respectfully requests that the Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal of the Company’s Registration Statement on Form S-1 (File No. 333-218250), together with all exhibits thereto (the “ Registration Statement ”), with such withdrawal to be effective as of the date hereof or as soon as practicable hereafter. The Registration Statement was filed with the Commission on May 26, 2017, amended on July 6, 2017 and was not declared effective.
Consistent with the public interest and the protection of investors contemplated by paragraph (a) of Rule 477 of the Securities Act, the Company is withdrawing this Registration Statement in response to communications with the Commission’s staff. The Company intends to file a new registration statement on Form S-1 to replace the Registration Statement. The Company confirms that no securities were sold in connection with the offering.
The Company further requests, in accordance with Rule 457(p) of the Securities Act, that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account with the Commission for future use.
If you have any questions regarding this matter, please contact the Company’s counsel, Brian A. Lebrecht of Clyde Snow & Sessions, P.C., at (801) 433-2453.
Very truly yours, | ||
/s/ William A. Hartman | ||
|
William A. Hartman | |
President | ||
Premier Biomedical, Inc. |
1 Year Premier Biomedical (PK) Chart |
1 Month Premier Biomedical (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions